- Home
- NYC vs SNTI Comparison
NYC vs SNTI Comparison
Compare NYC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | SNTI |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 22.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NYC | SNTI |
|---|---|---|
| Price | $8.75 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 2.9K | ★ 163.0K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $1.62 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.03 | $0.80 |
| 52 Week High | $16.30 | $5.10 |
Technical Indicators
Market Signals| Indicator | NYC | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 41.67 |
| Support Level | $7.12 | $0.80 |
| Resistance Level | $10.41 | $1.19 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 29.05 | 41.67 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.